arrow
N

Nikhil C. Munshi

Harvard Medical School
H指数:152
被引数:9.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Publisher Correction: Molecular predictors of minimal residual disease in newly diagnosed multiple myeloma treated with quadruplet therapy

Publisher更正:新诊断接受四联疗法治疗的多发性骨髓瘤的微小残留病分子预测因子

2026-11-030
OAAI
Molecular predictors of minimal residual disease in newly diagnosed multiple myeloma treated with quadruplet therapy

新诊断接受四联疗法治疗的多发性骨髓瘤中微小残留病的分子预测因子

2026-10-190
OAAI
WNK2 oncogenicity revealed by the discovery and functional characterization of novel gene isoforms in MYD88 mutated Waldenström’s Macroglobulinemia

WNK2致癌性通过在MYD88突变的华氏巨球蛋白血症中发现并功能表征新型基因异构体得以揭示

2026-07-080
OA
Ciltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trial

Ciltacabtagene autoleucel在高风险冒烟型多发性骨髓瘤中的应用:CAR-PRISM二期临床试验

2026-04-200
OAAI
Morbidity burden and healthcare costs in idiopathic multicentric Castleman disease (BURDEN-iMCD): a retrospective population-level matched cohort analysis

特发性多中心性Castleman病的患病负担及医疗成本(BURDEN-iMCD):一项回顾性基于人群的匹配队列分析

2026-01-010
OA
Distinct populations of vascular smooth muscle and sinoatrial progenitors are localized adjacent to pro-epicardium

血管平滑肌和窦房结祖细胞的独特种群定位于原心外膜相邻处

2025-11-180
OAAI
Putative multiple myeloma susceptibility genes identified by exome sequencing of 347 familial and early-onset cases

通过全外显子测序鉴定的347例家族性和早发性多发性骨髓瘤易感基因

Leukemia
IF13.4
2025-11-180
PRE
The endogenous T cell landscape is reshaped by CAR-T cell therapy and predicts treatment response in multiple myeloma

内源性T细胞景观被CAR-T细胞疗法重塑,并预测多发性骨髓瘤的治疗反应

Leukemia
IF13.4
2025-09-190
OAAI
Prospective study of immunogenicity to SARS-CoV-2 booster vaccines in multiple myeloma and Waldenström macroglobulinemia

多发性骨髓瘤和Waldenström巨球蛋白血症患者对SARS-CoV-2加强疫苗免疫原性的前瞻性研究

2025-06-090
OAAI
Isoform-Level Long Noncoding RNA Dependencies in Multiple Myeloma

多发性骨髓瘤中isoform水平的长链非编码RNA依赖性

BLOOD
IF23.1
2024-11-050
PRE
Outcomes of Patients By High-Risk Cytogenetic Abnormalities in a Phase II Study of Isatuximab, Weekly Carfilzomib, Lenalidomide, Dexamethasone in Newly Diagnosed, Multiple Myeloma (The SKylaRk Trial) Who Deferred Transplant

伊沙妥昔单抗、每周卡非佐米、来那度胺、地塞米松方案在初诊多发性骨髓瘤患者(SKylaRk试验)中,因延迟移植的高风险细胞遗传学异常患者的结局

BLOOD
IF23.1
2024-11-051
PRE
EASIX-guided risk stratification for complications and outcome after CAR T-cell therapy with ide-cel in relapsed/refractory multiple myeloma

EASIX指导的复发/难治性多发性骨髓瘤中使用ide-cel进行CAR T细胞治疗后并发症和结局的风险分层

2024-10-071
OAAI
Venetoclax resistance leads to broad resistance to standard-of-care anti-MM agents, but not to immunotherapies

Venetoclax耐药性导致对护理标准抗MM药物的广泛耐药性,但对免疫疗法没有

2024-07-290
OAAI